I was not surprised to learn about the failure of bapineuzumab, the drug Pfizer, Johnson & Johnson, and Elan were developing as a treatment for Alzheimer’s disease. Alzheimer’s is a VERY difficult area of R&D and I have talked previously about how tough this is. What has surprised me are the negative comments that have flowed from the failure of bapineuzumab on Twitter.
